Intrapleural interleukin-2–expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease

The Journal of Thoracic and Cardiovascular Surgery

article

Chigozirim N. Ekeke¹  Kira L. Russell²  Pranav Murthy²  Zong Sheng Guo²  Adam C. Soloff¹  Daniel Weber³  Wenjing Pan³  Michael T. Lotze²  Rajeev Dhupar¹ 

[1] Department of Cardiothoracic Surgery, University of Pittsburgh;Department of Surgery, University of Pittsburgh;iRepertoire, Inc, Hudson Alpha Institute for Biotechnology;Department of Immunology, University of Pittsburgh;Department of Bioengineering, University of Pittsburgh;Cancer Immunology and Immunotherapy Program, UPMC Hillman Cancer Center;Surgical Services Division, VAPHS, Pittsburgh, Pa关键词: IL-2;    immunotherapy;    intrapleural therapy;    malignant pleural disease;    malignant pleural effusion;    metastatic lung cancer;    oncolytic virotherapy;    PD-1;    vaccinia virus;   

DOI  :  10.1016/j.jtcvs.2020.11.160

学科分类：心脏病和心血管学

来源: Mosby, Inc.

【 摘 要 】

The mainstay of treatment for patients with malignant pleural disease is fluid drainage and systemic therapy. A tumor-specific oncolytic virus or T-cell–activating interleukin-2 immunotherapy may provide an opportunity for local control. We previously developed a vaccinia virus–expressing interleukin-2, an oncolytic virus that mediated tumor regression in preclinical peritoneal tumor models with expansion of tumor-infiltrating lymphocytes. We evaluated the antitumor efficacy and immune modulatory effects of vaccinia virus–expressing interleukin-2 in malignant pleural disease.

【 授权许可】

Unknown